2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

Inhibitory Antibodies

" in MedChemExpress (MCE) Product Catalog:

2253

Inhibitors & Agonists

6

Fluorescent Dye

3

Peptides

2630

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9993
    Peresolimab
    1 Publications Verification

    LY-3462817

    		 PD-1/PD-L1 Inflammation/Immunology
    Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. Peresolimab can be used in research of rheumatoid arthritis .
    Peresolimab
  • HY-P990047
    Maridebart

    AMG133 antibody

    		 GLP Receptor Metabolic Disease
    Maridebart is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody .
    Maridebart
  • HY-P99273
    Vorsetuzumab

    		TNF Receptor Cancer
    Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .
    Vorsetuzumab
  • HY-P991169
    Zemocimig

    		Factor Xa Cardiovascular Disease
    Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
    Zemocimig
  • HY-P991165
    Trovostobart

    		Fc Receptor (FcR) Others
    Trovostobart is an anti-VSIR human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Trovostobart
  • HY-P991170
    Ibramvibart

    		SARS-CoV Infection
    Ibramvibart is an anti-SARS-CoV-2 Spike human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Ibramvibart
  • HY-P991166
    Ubletamig

    		Mucin Others
    Ubletamig is an anti-MUC16 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
    Ubletamig
  • HY-P991115
    Adimanebart

    		Trk Receptor Others
    Amdokitug is an anti-MUSK human IgG1 λ monoclonal antibody. Recommend Isotype Controls: Human IgG1 Lambda2, Isotype Control (HY-P990096) .
    Adimanebart
  • HY-P991117
    Amrecibart

    		Factor Xa Cardiovascular Disease
    Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
    Amrecibart
  • HY-P991372
    Anti-TROP2 Antibody

    RN927C antibody

    		 TROP2 Cancer
    Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody (mAb) targeting TROP2. Anti-TROP2 Antibody has an inhibitory effect on multiple tumor cell lines in vitro. Anti-TROP2 Antibody has anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung LG0476 PDX, and triple-negative breast cancer (TNB) PDX models .
    Anti-TROP2 Antibody
  • HY-P99187
    Bococizumab

    PF-04950615; RN316

    		 PCSK9 Cardiovascular Disease Metabolic Disease
    Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .
    Bococizumab
  • HY-P991042
    Anti-IGFBP2 Antibody (M14)

    		IGF-1R Cancer
    Anti-IGFBP2 Antibody (M14) is an human anti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .
    Anti-IGFBP2 Antibody (M14)
  • HY-P99262
    Imalumab

    BAX69; Anti-Human MIF Recombinant Antibody

    		 Macrophage migration inhibitory factor (MIF) Cancer
    Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
    Imalumab
  • HY-P99514
    Zalifrelimab

    AGEN1884

    		 CTLA-4 Cancer
    Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
    Zalifrelimab
  • HY-P9901
    Ipilimumab
    4 Publications Verification

    MDX-010; BMS-734016

    		 CTLA-4 Cancer
    Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
    Ipilimumab
  • HY-P990247
    Anti-Mouse E-selectin/CD62E Antibody (9A9)

    		E-Selectin Inflammation/Immunology Cancer
    Anti-Mouse E-selectin/CD62E Antibody (9A9) is an anti-mouse E-selectin/CD62E IgG2b monoclonal antibody. Anti-Mouse E-selectin/CD62E Antibody (9A9) has an inhibitory effect on cancer cell colonization. Anti-Mouse E-selectin/CD62E Antibody (9A9) can be used for researches on inflammation conditions and cancer such as acute microvascular inflammation and breast cancer .
    Anti-Mouse E-selectin/CD62E Antibody (9A9)
  • HY-P990025
    Empasiprubart

    ARGX-117

    		 Complement System Inflammation/Immunology
    Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
    Empasiprubart
  • HY-P991228
    LYT-200

    		Galectin Cancer
    Lyt-200 is a humanized monoclonal antibody targeting Galectin-9. Lyt-200 exhibits potent inhibitory effects on hematological cancer cells and can also be used in combination with methotrexate (HY-14519) for research purposes .
    LYT-200
  • HY-P3371
    Ifinatamab deruxtecan

    DS-7300a; MABX-9001a

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Ifinatamab deruxtecan (DS-7300a) is an ADC that binds an anti-B7-H3 antibody to the DNA topoisomerase I inhibitory anti-tumor drug DXd. Ifinatamab deruxtecan has antitumor activity .
    Ifinatamab deruxtecan
  • HY-P991394
    SEA-TGT

    		Transmembrane Glycoprotein Cancer
    SEA-TGT is a human monoclonal antibody (mAb) targeting TIGIT. SEA-TGT enhances binding to the activating FcγRIIIA while reducing binding to the inhibitory FcγRIIb. SEA-TGT can be used in advanced solid tumors and Lymphoma research .
    SEA-TGT
  • HY-P99921
    Enapotamab vedotin

    HuMax-AXL-ADC

    		 Antibody-Drug Conjugates (ADCs) TAM Receptor Cancer
    Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). Enapotamab vedotin also exhibits resistant to EGFR inhibitor such as Osimertinib (HY-15772) .
    Enapotamab vedotin
  • HY-P990196
    Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2)

    		P-glycoprotein Cancer
    Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) is an anti-monkey/human MDR-1/CD243 IgG2a monoclonal antibody. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) can efficiently inhibit P-glycoprotein. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) enhances the inhibitory effect on multidrug resistance (MDR) by suppressing drug efflux. Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) can be used for research on cancer .
    Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2)
  • HY-P990031
    Dargistotug

    M-6223

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
    Dargistotug
  • HY-P99153
    Farletuzumab

    MORAb-003

    		 Antibiotic Cancer
    Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
    Farletuzumab
  • HY-P99044
    Sabatolimab
    1 Publications Verification

    MBG453

    		 Tim3 Inflammation/Immunology
    Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .
    Sabatolimab
  • HY-P99518
    Taldefgrobep alfa

    BMS 986089; RG 6206; RO 7239361; BHV2000

    		 TGF-beta/Smad Others
    Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research .
    Taldefgrobep alfa
  • HY-P991257
    MK-1966

    		Interleukin Related Cancer
    MK-1966 is a humanized monoclonal antibody inhibitor targeting interleukin-10 (IL-10). MK-1966 blocks the inhibitory effects of IL-10 on immune cells such as macrophages and dendritic cells to restore anti-tumor immune responses. MK-1966 is promising for research of cancers .
    MK-1966
  • HY-P99377
    Navicixizumab

    OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)

    		 Notch Cancer
    Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .
    Navicixizumab
  • HY-P99961
    Tifcemalimab

    JS004; Icatolimab

    		 CD28 Cancer
    Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer, such as lymphoma and non-small cell lung cancer (NSCLC) .
    Tifcemalimab
  • HY-P991370
    SBT-100

    		STAT Cancer
    SBT-100 is a human monoclonal antibody (mAb) targeting STAT3. SBT-100 inhibits IL-6-mediated P-STAT3 nuclear translocation in HEp-2 and PANC-1 cells. SBT-100 has tumor growth inhibitory effects on MDA-MB-231 .
    SBT-100
  • HY-P99419
    Acasunlimab

    GEN1046

    		 PD-1/PD-L1 Cancer
    Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .
    Acasunlimab
  • HY-P99623
    Flotetuzumab

    MGD006; S80880

    		 CD3 Cancer
    Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
    Flotetuzumab
  • HY-P991582
    BI-1607

    		Fc Receptor (FcR) Cancer
    BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
    BI-1607
  • HY-P99300
    Ligelizumab
    1 Publications Verification

    QGE 031; Anti-IGHE Recombinant Antibody

    		 Fc Receptor (FcR) Inflammation/Immunology
    Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
    Ligelizumab
  • HY-P991571
    GC1118

    GC-1118A

    		 EGFR PERK Akt Cancer
    GC1118 (GC-1118A) is a fully human anti-EGFR monoclonal antibody with binding affinity of 0.16 nM (KD) to EGFR. GC1118 displays potent inhibitory effects on high- and low-affinity EGFR ligand-induced signaling. GC1118 shows potent anti proliferative activity in KRAS wild-type and KRAS mutant cells. GC1118 can reach the tumor by crossing both BBB (blood-brain barrier) and BTB (brain-tumor barrier) and shows superior anti-tumor effects in various mice xenograft models. GC1118 can be used for the researches of cancer, such as colorectal cancer .
    GC1118
  • HY-P990068
    Perenostobart

    SRF617

    		 NTPDase Inflammation/Immunology Cancer
    Perenostobart (SRF617) is a human IgG4 antibody with inhibitory activity against CD39 ATPase. Perenostobart inhibits CD39-mediated hydrolysis of extracellular ATP to AMP, with IC50 values of 1.9 nM (HEK293 OE cells), 0.7 nM (MOLP-8 cells), and 1.2 nM (RBC-lysed whole blood). Perenostobart enhances CD4 + T-cell proliferation, promotes dendritic cell maturation, and boosts inflammasome activation in macrophages in the presence of ATP. Perenostobart demonstrates significant single-agent anti-tumor efficacy in MOLP-8 and H520 xenograft models. Perenostobart can be used for the study of cancer .
    Perenostobart
  • HY-P10091
    CD24/Siglec-10 blocking peptide, CSBP

    		PD-1/PD-L1 Cancer
    CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell .
    CD24/Siglec-10 blocking peptide, CSBP
  • HY-P4810
    Polyphemusin II-Derived Peptide

    T140

    		 CXCR Infection
    Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 .
    Polyphemusin II-Derived Peptide
  • HY-153908
    SMP-93566

    		Drug-Linker Conjugates for ADC Cancer
    SMP-93566 is a kind of antibody-drug conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .
    SMP-93566
  • HY-153907
    SMP-88480

    		Drug-Linker Conjugates for ADC Cancer
    SMP-88480 is an Antibody-Drug Conjugates (ADCs). SMP-88480 is stable in mouse, monkey and human plasma and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .
    SMP-88480
  • HY-P9921
    Trastuzumab emtansine
    3 Publications Verification

    Ado-Trastuzumab emtansine; PRO132365; T-DM 1

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine
  • HY-P9921A
    Trastuzumab emtansine (solution)
    3 Publications Verification

    Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine (solution)
  • HY-D2460
    Dextran-CY5.5

    		Fluorescent Dye Bacterial Cardiovascular Disease Cancer
    Dextran-CY5.5 is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673nm and the emission wavelength is 707nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
    Dextran-CY5.5
  • HY-P991610
    S-095029

    Sym025

    		 C-type Lectin-like Receptors (CTLRs) Cancer
    S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
    S-095029
  • HY-P99605
    Cinrebafusp alfa

    PRS 343

    		 EGFR TNF Receptor Cancer
    Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .
    Cinrebafusp alfa
  • HY-P991408
    DLX-105

    		TNF Receptor Interleukin Related IFNAR Inflammation/Immunology
    DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research .
    DLX-105
  • HY-P991409
    GSK2800528

    		TNF Receptor Inflammation/Immunology
    GSK2800528 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. GSK2800528 can be used in inflammation and psoriasis research .
    GSK2800528
  • HY-P99124
    Anti-Mouse CD3 Antibody (17A2)
    1 Publications Verification

    		 CD3 Inflammation/Immunology
    Anti-Mouse CD3 Antibody (17A2) is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat. Anti-Mouse CD3 Antibody (17A2) enhances T-cell proliferation and activation and stimulate IFN-γ or IL-17 production in splenic T cells. Anti-Mouse CD3 Antibody (17A2) significantly suppresses mortality in Graft-versus-host disease (GVHD) mice models .
    Anti-Mouse CD3 Antibody (17A2)
  • HY-P99399
    Semorinemab

    RG 6100; RO7105705; MTAU-9937A

    		 Tau Protein Neurological Disease
    Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
    Semorinemab
  • HY-P991604
    MLN2201

    YFC51.1; LDP-01

    		 Integrin Inflammation/Immunology
    MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .
    MLN2201

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: